Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Skip Nav Destination
David Sallman: Magrolimab Plus Azacitidine Effective in MDS and AML
December 30, 2021
Content License:Private